Sunday, 26 April 2009

Scheriderm




Scheriderm may be available in the countries listed below.


Ingredient matches for Scheriderm



Isoconazole

Isoconazole nitrate (a derivative of Isoconazole) is reported as an ingredient of Scheriderm in the following countries:


  • Peru

International Drug Name Search

Thursday, 23 April 2009

Diguan




Diguan may be available in the countries listed below.


Ingredient matches for Diguan



Metformin

Metformin is reported as an ingredient of Diguan in the following countries:


  • Romania

International Drug Name Search

Domedol




Domedol may be available in the countries listed below.


Ingredient matches for Domedol



Allopurinol

Allopurinol is reported as an ingredient of Domedol in the following countries:


  • Vietnam

International Drug Name Search

Wednesday, 22 April 2009

Incremin




Incremin may be available in the countries listed below.


Ingredient matches for Incremin



Ferric Pyrophosphate

Ferric Pyrophosphate is reported as an ingredient of Incremin in the following countries:


  • Japan

International Drug Name Search

Tuesday, 21 April 2009

Deconex


Generic Name: guaifenesin and phenylephrine (gwye FEN e sin and FEN il EFF rin)

Brand Names: Aldex G, Aquatab D, Crantex, D-Phen 1000, D-Tab, Deconex, Deconsal II, Deconsal Pediatric, Despec, Donatussin Drops, Duomax, Duraphen 1000, Duraphen II, Duratuss, Dynex LA, ExeTuss, Extendryl G, Fenesin PE IR, Genexa LA, Gentex LA, Gilphex TR, Guaiphen-D 1200, Guaiphen-D 600, Guaiphen-PD, Guiadex PD, Guiatex PE, J-Max, Liquibid D-R, Liquibid-D, Liquibid-PD, Lusonex, Maxiphen, Medent-PE, MontePhen, Mucinex Children's Cold, Mucus Relief Sinus, Mydex, Nariz, Nasex, Nescon-PD, Nexphen PD, Norel EX, PE-Guai, Pendex, Prolex D, Refenesen PE, Reluri, Rescon-GG, Respa-PE, Robitussin Head & Chest Congestion, Simuc, Simuc-GP, Sina-12X, Sinupan, SINUvent PE, Sitrex PD, Sudafed PE Non-Drying Sinus, Sudex, Triaminic Chest & Nasal Congestion, Visonex, Wellbid-D, Xedec, Xedec II, Xpect-PE, Zotex GPX


What is Deconex (guaifenesin and phenylephrine)?

There are many brands and forms of guaifenesin and phenylephrine available and not all brands are listed on this leaflet.


Guaifenesin is an expectorant. It helps loosen congestion in your chest and throat, making it easier to cough out through your mouth.


Phenylephrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).


The combination of guaifenesin and phenylephrine is used to treat stuffy nose and sinus congestion, and to reduce chest congestion caused by the common cold or flu.


Guaifenesin and phenylephrine may also be used for purposes not listed in this medication guide.


What is the most important information I should know about Deconex (guaifenesin and phenylephrine)?


There are many brands and forms of guaifenesin and phenylephrine available and not all brands are listed on this leaflet.


Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Ask a doctor or pharmacist before using any other cough, cold, or allergy medicine. Guaifenesin and phenylephrine are contained in many combination medicines. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains guaifenesin or phenylephrine.

What should I discuss with my healthcare provider before taking Deconex (guaifenesin and phenylephrine)?


You should not use this medication if you are allergic to guaifenesin or phenylephrine, or to other decongestants, diet pills, stimulants, or ADHD medications. Do not use guaifenesin and phenylephrine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. Serious, life threatening side effects can occur if you use guaifenesin and phenylephrine before the MAO inhibitor has cleared from your body.

Ask a doctor or pharmacist if it is safe for you to take this medication if you have:



  • heart disease or high blood pressure;




  • diabetes;




  • circulation problems;




  • glaucoma;




  • overactive thyroid; or




  • enlarged prostate or problems with urination.




It is not known if this medication may be harmful to an unborn baby. Do not use this medication without your doctor's advice if you are pregnant. This medication passes into breast milk and could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

Artificially-sweetened liquid forms of cold medicine may contain phenylalanine. This would be important to know if you have phenylketonuria (PKU). Check the ingredients and warnings on the medication label if you are concerned about phenylalanine.


How should I take Deconex (guaifenesin and phenylephrine)?


Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Cold medicine is usually taken only for a short time until your symptoms clear up.


Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving cough or cold medicine to a child. Death can occur from the misuse of cough or cold medicine in very young children.

Measure the liquid form of this medicine with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.


Do not crush, chew, break, or open an extended-release tablet or capsule. Swallow it whole. Breaking or opening the pill may cause too much of the drug to be released at one time. Take guaifenesin and phenylephrine with food if it upsets your stomach. Talk with your doctor if your symptoms do not improve after 7 days of treatment, or if you have a fever with a headache, cough, or skin rash. Drink extra fluids to help loosen the congestion and lubricate your throat while you are taking this medication. Store at room temperature away from moisture and heat.

What happens if I miss a dose?


Since cough or cold medicine is taken as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include nausea, vomiting, numbness or tingly feeling, dizziness, and feeling restless or nervous.


What should I avoid while taking Deconex (guaifenesin and phenylephrine)?


This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Drinking alcohol can increase certain side effects of guaifenesin and phenylephrine. Ask a doctor or pharmacist before using any other cough, cold, or allergy medicine. Guaifenesin and phenylephrine are contained in many combination medicines. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains guaifenesin or phenylephrine.

Avoid taking this medication with diet pills, caffeine pills, or other stimulants (such as ADHD medications) without your doctor's advice. Taking a stimulant together with a decongestant can increase your risk of unpleasant side effects.


Deconex (guaifenesin and phenylephrine) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have any of these serious side effects:

  • fast, pounding, or uneven heartbeat;




  • severe dizziness, anxiety, restless feeling, or nervousness;




  • easy bruising or bleeding, unusual weakness, fever, chills, body aches, flu symptoms;




  • dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure); or




  • nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).



Less serious side effects may include:



  • vomiting, upset stomach;




  • warmth, tingling, or redness under your skin;




  • feeling excited or restless (especially in children);




  • sleep problems (insomnia);




  • skin rash or itching;




  • headache; or




  • dizziness.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Deconex (guaifenesin and phenylephrine)?


Ask a doctor or pharmacist if it is safe for you to take guaifenesin and phenylephrine if you are also using any of the following drugs:



  • medicines to treat high blood pressure;




  • a beta-blocker such as atenolol (Tenormin, Tenoretic), carvedilol (Coreg), labetalol (Normodyne, Trandate), metoprolol (Dutoprol, Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal, InnoPran), sotalol (Betapace), and others; or




  • an antidepressant such as amitriptyline (Elavil, Vanatrip, Limbitrol), doxepin (Sinequan, Silenor), desipramine (Norpramin), imipramine (Janimine, Tofranil), nortriptyline (Pamelor), and others.



This list is not complete and other drugs may interact with guaifenesin and phenylephrine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Deconex resources


  • Deconex Side Effects (in more detail)
  • Deconex Use in Pregnancy & Breastfeeding
  • Deconex Drug Interactions
  • Deconex Support Group
  • 0 Reviews for Deconex - Add your own review/rating


  • Crantex Prescribing Information (FDA)

  • Despec Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Entex LA Sustained-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)

  • Gentex LA Sustained-Release Tablets (12 Hour) MedFacts Consumer Leaflet (Wolters Kluwer)

  • Guiatex PE Prescribing Information (FDA)

  • Lusonex Controlled-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Rescon-GG Liquid MedFacts Consumer Leaflet (Wolters Kluwer)

  • Sina-12X Suspension MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Deconex with other medications


  • Cough and Nasal Congestion
  • Sinus Symptoms


Where can I get more information?


  • Your pharmacist can provide more information about guaifenesin and phenylephrine.

See also: Deconex side effects (in more detail)


Wednesday, 15 April 2009

Efudix




Efudix may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

UK matches:

  • Efudix 5% Cream
  • Efudix Cream (SPC)

Ingredient matches for Efudix



Fluorouracil

Fluorouracil is reported as an ingredient of Efudix in the following countries:


  • Argentina

  • Australia

  • Belgium

  • Bulgaria

  • Chile

  • Costa Rica

  • Dominican Republic

  • El Salvador

  • France

  • Germany

  • Guatemala

  • Honduras

  • Hungary

  • Ireland

  • Israel

  • Luxembourg

  • Malta

  • Mexico

  • Netherlands

  • New Zealand

  • Nicaragua

  • Panama

  • Peru

  • Poland

  • Romania

  • Serbia

  • Singapore

  • Slovakia

  • South Africa

  • Switzerland

  • Taiwan

  • United Kingdom

International Drug Name Search

Glossary

SPC Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Couldrex




Couldrex may be available in the countries listed below.


Ingredient matches for Couldrex



Paracetamol

Paracetamol is reported as an ingredient of Couldrex in the following countries:


  • New Zealand

Pseudoephedrine

Pseudoephedrine hydrochloride (a derivative of Pseudoephedrine) is reported as an ingredient of Couldrex in the following countries:


  • New Zealand

International Drug Name Search

Monday, 13 April 2009

Abinac




Abinac may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Abinac



Acetylcysteine

Acetylcysteine is reported as an ingredient of Abinac in the following countries:


  • Italy

International Drug Name Search

Thursday, 9 April 2009

Effexor XR


Effexor XR is a brand name of venlafaxine, approved by the FDA in the following formulation(s):


EFFEXOR XR (venlafaxine hydrochloride - capsule, extended release; oral)



  • Manufacturer: WYETH PHARMS INC

    Approval date: October 20, 1997

    Strength(s): EQ 150MG BASE [RLD][AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]

Has a generic version of Effexor XR been approved?


A generic version of Effexor XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Effexor XR and have been approved by the FDA:


venlafaxine hydrochloride capsule, extended release; oral



  • Manufacturer: AUROBINDO PHARMA LTD

    Approval date: April 14, 2011

    Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]


  • Manufacturer: DR REDDYS LABS LTD

    Approval date: May 6, 2011

    Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]


  • Manufacturer: MYLAN

    Approval date: June 1, 2011

    Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]


  • Manufacturer: ORCHID HLTHCARE

    Approval date: July 11, 2011

    Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]


  • Manufacturer: TEVA

    Approval date: June 28, 2010

    Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]


  • Manufacturer: TORRENT PHARMS LLC

    Approval date: June 1, 2011

    Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]


  • Manufacturer: VALEANT INTL

    Approval date: April 15, 2011

    Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]


  • Manufacturer: WOCKHARDT

    Approval date: April 14, 2011

    Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]


  • Manufacturer: ZYDUS PHARMS USA INC

    Approval date: April 14, 2011

    Strength(s): EQ 150MG BASE [AB], EQ 37.5MG BASE [AB], EQ 75MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Effexor XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Venlafaxine for the treatment of generalized anxiety disorder
    Patent 5,916,923
    Issued: June 29, 1999
    Inventor(s): Rudolph; Richard L. & Upton; G. Virginia
    Assignee(s): American Home Products Corporation
    This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia iervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: ##STR1## in which A is a moiety of the formula ##STR2## where the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl; R.sub.2 is alkyl; R.sub.4 is hydrogen, alkyl, formyl, or alkanol; R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, aakyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.
    Patent expiration dates:

    • June 28, 2013
      ✓ 
      Patent use: TREATMENT OF GENERALIZED ANXIETY DISORDER


    • December 28, 2013
      ✓ 
      Patent use: TREATMENT OF GENERALIZED ANXIETY DISORDER
      ✓ 
      Pediatric exclusivity




  • Extended release formulation of venlafaxine hydrochloride
    Patent 6,274,171
    Issued: August 14, 2001
    Inventor(s): Sherman; Deborah M. & Clark; John C. & Lamer; John U. & White; Steven A.
    Assignee(s): American Home Products Corporation
    This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
    Patent expiration dates:

    • March 20, 2017


    • September 20, 2017
      ✓ 
      Pediatric exclusivity




  • Treatments using venlafaxine
    Patent 6,310,101
    Issued: October 30, 2001
    Inventor(s): Rudolph; Richard L. & Derivan; Albert T. & Muth; Eric A. & Upton; G. Virginia
    Assignee(s): American Home Products Corporation
    This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: ##STR1## in which A is a moiety of the formula ##STR2## where the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl; R.sub.2 is alkyl; R.sub.4 is hydrogen, alkyl, formyl, or alkanol; R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.
    Patent expiration dates:

    • June 28, 2013
      ✓ 
      Patent use: TREATMENT OF PANIC DISORDER




  • Extended release formulation of venlafaxine hydrochloride
    Patent 6,403,120
    Issued: June 11, 2002
    Inventor(s): Deborah M.; Sherman & John C.; Clark & John U.; Lamer & Steven A.; White
    Assignee(s): Wyeth
    This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and fiber provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
    Patent expiration dates:

    • March 20, 2017
      ✓ 
      Patent use: TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER


    • March 20, 2017
      ✓ 
      Patent use: TREATMENT OF SOCIAL ANXIETY DISORDER


    • September 20, 2017
      ✓ 
      Patent use: TREATMENT OF SOCIAL ANXIETY DISORDER
      ✓ 
      Pediatric exclusivity


    • September 20, 2017
      ✓ 
      Patent use: TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
      ✓ 
      Pediatric exclusivity




  • Extended release formulation of venlafaxine hydrochloride
    Patent 6,419,958
    Issued: July 16, 2002
    Inventor(s): Deborah M.; Sherman & John C.; Clark & John U.; Lamer & Steven A.; White
    Assignee(s): Wyeth
    This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
    Patent expiration dates:

    • March 20, 2017
      ✓ 
      Patent use: TREATMENT OF SOCIAL ANXIETY DISORDER


    • March 20, 2017
      ✓ 
      Patent use: TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER


    • September 20, 2017
      ✓ 
      Patent use: TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
      ✓ 
      Pediatric exclusivity


    • September 20, 2017
      ✓ 
      Patent use: TREATMENT OF SOCIAL ANXIETY DISORDER
      ✓ 
      Pediatric exclusivity




  • Treatment using venlafaxine
    Patent 6,444,708
    Issued: September 3, 2002
    Inventor(s): Richard L.; Rudolph & Albert T.; Derivan & G. Virginia; Upton
    Assignee(s): Wyeth
    This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: in which A is a moiety of the formula where the dotted line represents optional unsaturation; R1 is hydrogen or alkyl; R2 is alkyl; R4 is hydrogen, alkyl, formyl, or alkanol; R5 and R6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.
    Patent expiration dates:

    • June 28, 2013
      ✓ 
      Patent use: TREATMENT OF GENERALIZED ANXIETY DISORDER


    • December 28, 2013
      ✓ 
      Patent use: TREATMENT OF GENERALIZED ANXIETY DISORDER
      ✓ 
      Pediatric exclusivity



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 14, 2010 - LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER

See also...

  • Effexor XR Extended-Release Capsules Consumer Information (Wolters Kluwer)
  • Effexor XR Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Effexor XR Consumer Information (Cerner Multum)
  • Effexor-XR Advanced Consumer Information (Micromedex)
  • Venlafaxine Consumer Information (Drugs.com)
  • Venlafaxine Consumer Information (Wolters Kluwer)
  • Venlafaxine Extended-Release Capsules Consumer Information (Wolters Kluwer)
  • Venlafaxine Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Venlafaxine Consumer Information (Cerner Multum)
  • Venlafaxine Advanced Consumer Information (Micromedex)
  • Venlafaxine Hydrochloride AHFS DI Monographs (ASHP)

Monday, 6 April 2009

Tazobac




Tazobac may be available in the countries listed below.


Ingredient matches for Tazobac



Piperacillin

Piperacillin sodium salt (a derivative of Piperacillin) is reported as an ingredient of Tazobac in the following countries:


  • Germany

  • Italy

  • Portugal

  • Switzerland

Tazobactam

Tazobactam sodium salt (a derivative of Tazobactam) is reported as an ingredient of Tazobac in the following countries:


  • Germany

  • Italy

  • Portugal

  • Switzerland

International Drug Name Search

Saturday, 4 April 2009

Dopamin




Dopamin may be available in the countries listed below.


Ingredient matches for Dopamin



Dopamine

Dopamine hydrochloride (a derivative of Dopamine) is reported as an ingredient of Dopamin in the following countries:


  • Norway

  • Poland

  • Serbia

International Drug Name Search